VolitionRX

VNRX

Market cap $50.6M

HENDERSON, Nev. , Oct. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 11,550,000 shares of its common stock and warrants to purchase up to 11,550,000 shares of its common stock.

HENDERSON, Nev. , Oct. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it is proposing to offer and sell, in an underwritten public offering, shares of its common stock and accompanying common stock purchase warrants.

VolitionRx Limited - Special Call Company Participants Marielle Herzog Conference Call Participants Alexandra Byrne Eric Ariazi Presentation Alexandra Byrne Great. Good morning, everyone.

HENDERSON, Nev. , Oct. 2, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the sponsorship of a GenomeWeb webinar entitled "Beyond the Genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery" on Wednesday, October 8 (details can be found below).

HENDERSON, Nev. , Sept. 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with Hologic Diagenode ("Hologic") for the co-marketing of Volition's Nu.Q® Discover service.

HENDERSON, Nev. , Sept. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the signing of a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome ("APS") with Werfen's Immunoassay Technology Center, a worldwide leader in specialized diagnostics.

VolitionRx Limited (NYSE:VNRX ) Q2 2025 Earnings Conference Call August 15, 2025 8:30 AM ET Company Participants Andrew Retter - Chief Medical Officer Cameron Reynolds - Founder, CEO, President & Director Louise Batchelor Day - Group Chief Marketing & Communications Officer Terig Hughes - CFO & Treasurer Conference Call Participants Bruce David Jackson - The Benchmark Company, LLC, Research Division Jason Howard Kolbert - D. Boral Capital LLC, Research Division Justin Howard Walsh - JonesTrading Institutional Services, LLC, Research Division Yi Chen - H.C.

Conference call to discuss financial and operational results scheduled for Friday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

Conference call to take place on Friday, August 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.

HENDERSON, Nev. , Aug. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of (i)  156,250 shares of its common stock to certain directors and executive officers of the Company (collectively, the "Insiders") at an offering price of $0.64 per share, and (ii) 1,734,375 shares of its common stock, together with common stock purchase warrants to purchase up to 1,734,375 shares of common stock (individually, a "Warrant" and collectively, the "Warrants"), to certain other existing stockholders of the Company at a combined offering price of $0.64 per share and accompanying Warrant.